The University of Oxford is launching a study investigating the delivery of the ChAdOx1 nCoV-19 coronavirus vaccine using a nasal spray.
The Phase I trial, which will enrol 30 healthy volunteers aged 18–40, will investigate the level of immune system responses generated by the vaccine using this delivery technique, as well as monitoring safety and for any adverse reactions.
All of the volunteers will receive the same vaccine that is currently being delivered by intramuscular injection as part of the national roll out of the ChAdOx1 nCoV-19 vaccine. The volunteers, who will be drawn from the local Oxford region, will be followed for a total of four months.
Dr Sandy Douglas, Clinician-Scientist and Chief Investigator of the study said:
The vaccine will be delivered using an intranasal spray device, similar to many over-the-counter hay fever nasal sprays.
Dr Douglas adds:
Dr Meera Madhavan, Lead Clinical Research Fellow, Jenner Institute said:
Professor Adrian Hill, Director the Jenner Institute and Principal Investigator of the study said:
For further information on the trial, including how to participate, visit: www.jenner.ac.uk/volunteer/recruiting-trials/covid-19-vaccine-intranasal-study-cov008